oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice
Örebro University, School of Health and Medical Sciences.ORCID iD: 0000-0003-0122-7234
Show others and affiliations
2011 (English)In: Journal of Clinical Investigation, ISSN 0021-9738, E-ISSN 1558-8238, Vol. 121, no 5, p. 1733-1747Article in journal (Refereed) Published
Abstract [en]

Expression of the transmembrane glycoprotein CD98 (encoded by SLC3A2) is increased in intestinal inflammatory conditions, such as inflammatory bowel disease (IBD), and in various carcinomas, yet its pathogenetic role remains unknown. By generating gain- and loss-of-function mouse models with genetically manipulated CD98 expression specifically in intestinal epithelial cells (IECs), we explored the role of CD98 in intestinal homeostasis, inflammation, and colitis-associated tumorigenesis. IEC-specific CD98 overexpression induced gut homeostatic defects and increased inflammatory responses to DSS-induced colitis, promoting colitis-associated tumorigenesis in mice. Further analysis indicated that the ability of IEC-specific CD98 overexpression to induce tumorigenesis was linked to its capacity to induce barrier dysfunction and to stimulate cell proliferation and production of proinflammatory mediators. To validate these results, we constructed mice carrying conditional floxed Slc3a2 alleles and crossed them with Villin-Cre mice such that CD98 was downregulated only in IECs. These mice exhibited attenuated inflammatory responses and resistance to both DSS-induced colitis and colitis-associated tumorigenesis. Together, our data show that intestinal CD98 expression has a crucial role in controlling homeostatic and innate immune responses in the gut. Modulation of CD98 expression in IECs therefore represents a promising therapeutic strategy for the treatment and prevention of inflammatory intestinal diseases, such as IBD and colitis-associated cancer.

Place, publisher, year, edition, pages
American Society for Clinical Investigation , 2011. Vol. 121, no 5, p. 1733-1747
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:oru:diva-27410DOI: 10.1172/JCI44631ISI: 000290246800010PubMedID: 21490400Scopus ID: 2-s2.0-79955485553OAI: oai:DiVA.org:oru-27410DiVA, id: diva2:603694
Note

Funding Agencies:

Department of Veterans Affairs  

National Institute of Diabetes and Digestive and Kidney Diseases  R24-DK-064399  R01DK071594  RO1-DK-55850 

Crohn's and Colitis Foundation of America 

Available from: 2013-02-06 Created: 2013-02-06 Last updated: 2018-02-19Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Halfvarson, Jonas

Search in DiVA

By author/editor
Halfvarson, Jonas
By organisation
School of Health and Medical Sciences
In the same journal
Journal of Clinical Investigation
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 289 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf